Search
Raleigh, NC Paid Clinical Trials
A listing of 198 clinical trials in Raleigh, NC actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
37 - 48 of 198
There are currently 198 clinical trials in Raleigh, North Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including GSK Investigational Site, Wake Research Associates, Wake Research Associates, LLC and Pfizer Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
Featured Trial
Chronic Kidney Disease (CKD) Clinical Study
Recruiting
A clinical study for people that suffer with Chronic Kidney Disease (CKD)
Conditions:
Chronic Kidney Disease (CKD)
Featured Trial
Ischemic heart disease (IHD) Clinical Study
Recruiting
A clinical study for people that suffer with Ischemic heart disease (IHD)
Conditions:
Ischemic heart disease (IHD)
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
Recruiting
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular \[CV\] death, myocardial infarction \[MI\], and ischemic stroke).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Rex Hospital, Raleigh, North Carolina
Conditions: Acute Coronary Syndrome
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
Recruiting
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from a switch to ofatumumab.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
08/14/2025
Locations: Velocity Clinical Research, Raleigh, North Carolina
Conditions: Relapsing-Remitting Multiple Sclerosis
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
Recruiting
This study will evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of a new dosage of ofatumumab compared to the approved dosage of ofatumumab followed by extended treatment in participants with relapsing multiple sclerosis.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/14/2025
Locations: Velocity Clinical Research, Raleigh, North Carolina
Conditions: Relapsing Multiple Sclerosis (RMS)
SIMPLAAFY Clinical Trial
Recruiting
The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Rex Hospital, Raleigh, North Carolina +1 locations
Conditions: Atrial Fibrillation, Stroke, Bleeding
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
Recruiting
Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity. AD dementia is the most common type of dementia. AChEI therapy is the standard treatment for AD dementia.
The goals of this study are to learn:
* If at least one dose level (amount) of MK-1167 works to improve a person's memory and thinking compared to a placebo
* About... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
08/13/2025
Locations: Velocity Clinical Research - Raleigh ( Site 0123), Raleigh, North Carolina
Conditions: Alzheimer Disease, Dementia
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
Recruiting
The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices for the treatment of lesions located in the peripheral vasculature.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Rex UNC Health (NC Heart and Vascular Research, LLC), Raleigh, North Carolina
Conditions: Peripheral Vascular Diseases
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Recruiting
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: UNC Rex Cancer Center, Raleigh, North Carolina
Conditions: Triple Negative Breast Cancer
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Recruiting
This prospective longitudinal study will compare incidence rates of Medicare beneficiary surgical and minimally invasive intervention post index procedure, as well as harms associated with the MILD procedure, at 24 months post-treatment with MILD, tested against a control group of similar patients that have had a comparable procedure. This study will start with patients treated with a study procedure having an index date on or after January 1, 2017, and enrollment will continue until stopped by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Blue Ridge Surgery Center, Raleigh, North Carolina +6 locations
Conditions: Lumbar Spinal Stenosis
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
Recruiting
The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 1 to 4 other available medications to prevent their migraines, but these medications have not helped them.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/13/2025
Locations: Raleigh Medical Group, Raleigh, North Carolina +1 locations
Conditions: Migraine
Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx
Recruiting
The purpose of this study is to use intra-treatment 18FDG-PET/CT during definitive radiation therapy for human papillomavirus (HPV)-related oropharyngeal cancer (OPC) as an imaging biomarker to identify and select patients with a favorable response for chemoradiation dose de-escalation. This study will prospectively evaluate the clinical outcomes for patients undergoing dose de-escalation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Duke Raleigh Hospital, Raleigh, North Carolina
Conditions: Oropharynx Cancer
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Recruiting
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria.
Study details include:
* This eve... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/12/2025
Locations: Raleigh Neurology Associates- Site Number : 8400014, Raleigh, North Carolina
Conditions: Multiple Sclerosis
Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
Recruiting
This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread from where it first started (primary site) to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Duke Cancer Center Raleigh, Raleigh, North Carolina
Conditions: Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
37 - 48 of 198